Stock TAK N TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Takeda Pharmaceutical Company Limited Mexican S.E.

Equities

TAK N

US8740602052

End-of-day quote Mexican S.E.
Other stock markets
 06:00:00 2024-06-19 pm EDT 		5-day change 1st Jan Change
231.5 MXN -3.73% Intraday chart for Takeda Pharmaceutical Company Limited -.--% -3.42%
Jul. 03 Blackstone selling Japan drugmaker Alinamin to MBK Partners RE
Jul. 02 Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
China's Supreme People's Court Clarifies Priority Examination Standard in Recent Ruling
AQ
China's SPC Clarifies Priority Examination Standard In Recent Ruling
AQ
Blackstone selling Japan drugmaker Alinamin to MBK Partners
RE
Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan
MT
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan
CI
Codexis Sells Fabry, Pompe Disease Compounds to Crosswalk Therapeutics
MT
Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited.
CI
Takeda Pharmaceutical : Annual Securities Report (Part 1. Information on Takeda, IV. Information on the Company, 4. Corporate Governance)
PU
Takeda Announces the Publication of its Annual Report on Form 20-F for FY2023
AQ
TAKEDA PHARMACEUTICAL : Form 6 K
PU
Takeda Pharmaceutical : Announces New Assignments of Directors Form 6 K
PU
Takeda Announces New Assignments of Directors
BU
Transcript : Takeda Pharmaceutical Company Limited - Shareholder/Analyst Call
US CDC alerts healthcare providers of increase in dengue cases
RE
Takeda's Cancer Drug Gets European Commission Approval
MT
Hutchmed China notes Takeda obtains EU approval for Fruzaqla
AN
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators
MT
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment
MT
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
BU
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TAK N Stock
  5. News Takeda Pharmaceutical Company Limited